Legal Representation
Attorney
Robin Lightner Maisashvili
USPTO Deadlines
Next Deadline
2164 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-06-24)
Due Date
June 24, 2031
Grace Period Ends
December 24, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
42 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 24, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jun 24, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 2, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jun 2, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| May 9, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| May 5, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| May 5, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Apr 23, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 23, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Apr 16, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 16, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Oct 17, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 17, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Oct 17, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 17, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 12, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 11, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 11, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Apr 11, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 13, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 11, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Oct 11, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Oct 11, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 18, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 21, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 21, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 1, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 17, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 11, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 11, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 11, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 11, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 12, 2022 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Dec 5, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 1, 2022 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Nov 1, 2022 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Aug 29, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 29, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 29, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 25, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 30, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 29, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Promoting collaboration within the scientific, research, pharmaceutical, and medical communities to achieve advances in healthcare, including to accelerate the development and use of immunotherapy in treatment of disease
First Use Anywhere:
Nov 14, 2023
First Use in Commerce:
Nov 14, 2023
Class 036
Charitable fundraising services
First Use Anywhere:
Sep 30, 2024
First Use in Commerce:
Sep 30, 2024
Class 042
Medical research services; medical research, development, technical design, testing, and analysis services in the field of immunobiology, immunotherapy, antibodies, and oncology; consulting services in the field of immunobiology, immunotherapy, antibodies, and oncology; medical research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; medical research services in the field of immune repertoire analysis and the genome; scientific research in the fields of immunobiology, immunotherapy, antibodies and oncology; biological research; laboratory research services in the fields of immunobiology, immunotherapy, antibodies, oncology, and cellular engineering; medical laboratory services; providing information on medical and scientific research in the field of immunobiology and immunotherapy; medical and scientific research for others in the field of stem cell research, cancer, immunobiology and immunotherapy; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research liaison services, namely, consulting in the field of scientific research pertaining to clinical trials in the fields of health care, medicine, immunobiology, immunotherapy, pharmacology and biotechnology; collection and management of medical and scientific data for research purposes in the field of medical and scientific research; Pharmaceutical research services; Pharmaceutical research services relating to cancer
First Use Anywhere:
Jul 19, 2023
First Use in Commerce:
Jul 19, 2023
Class 044
Medical services; Medical services relating to cancer; providing medical information; providing health information in the field of immunobiology, immunotherapy, oncology and diseases; providing a
web site featuring medical information; providing a web site featuring health information in the field of immunobiology, immunotherapy, oncology and diseases; providing medical information, consultancy
and advisory services; providing information on cancer treatment; providing medical information to patients and medical professionals in the field of immunotherapy and cancer treatment
First Use Anywhere:
Sep 30, 2024
First Use in Commerce:
Sep 30, 2024
Classification
International Classes
035
036
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"INSTITUTE"